Group 1 - In May 2025, the number of newly registered private equity and venture capital fund managers in China dropped to 2, a decrease of 83.3% compared to April and a 60% decline year-on-year [1] - A total of 339 new private equity and venture capital funds were registered, marking a year-on-year increase of 55.5% but a month-on-month decrease of 18.7% [1] - The domestic primary equity investment market recorded 428 financing events, representing a year-on-year decrease of 13.6% and a month-on-month decrease of 18.0% [1] Group 2 - Shenzhen Innovation Investment Group (Deep Venture) has registered a new fund, the Shenzhen Hongtu Seed Fund, with a total capital contribution of 300 million yuan, focusing on advanced technology sectors [2] - The Shenzhen Semiconductor and Integrated Circuit Industry Investment Fund aims for a total scale of 5 billion yuan, with 3.6 billion yuan already contributed by various local government funds [3] Group 3 - Deep Venture disclosed 10 equity investment events in the reporting period, a fivefold increase compared to May 2024 and a 66.7% increase from April [3] - In the first five months of 2025, Deep Venture made 43 investments, which is 58.1% of its total investments in 2024 [3] Group 4 - 60% of Deep Venture's projects in May were in the angel and A-round early stages, with a focus on advanced manufacturing, particularly in integrated circuits and aerospace [6] - The company invested in "Sailu Medical," which completed an A+ round of financing, with funds aimed at expanding its sequencing platform and global market outreach [11][12]

导读： 赛陆医疗完成A+轮融资，复星医药领投，资金用于国产测序平台升级与市场扩展，推动生命科学工具创新。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，深圳赛陆医疗科技有限公司（以下简称：赛陆医疗）宣布完成A+轮融资。本轮融资由医疗健康行业龙头企业复星医药领投，常州伟驰投 资跟投，老股东深创投继续追加投资。本轮资金将重点用于全国产测序平台的注册申报、产能扩建及全球化市场拓展，进一步巩固其在生命科 学工具领域的创新引领地位。 自2020年成立以来，赛陆医疗发展始终保持快速步伐，2025年1月，赛陆医疗自主研发的Salus Pro测序仪获国家药监局（NMPA）三类医 疗器械注册证，2025年3月13日，赛陆医疗全资子公司——上海赛陆生命科学有限公司（简称"赛陆生科"）在上海宝山区隆重举行开业庆典 暨战略合作签约仪式，标志着赛陆测序平台在长三角的生产基地正式投入运营。 该公司坚持以"技术自主+产业闭环"为核心，已建成光学、流体、芯片、试剂等全链条研发体系，打造全国产化测序+超分辨空间组学平台，累 计授权专利超百项，产品覆盖科研、临 ...

2025年1月，赛陆医疗自主研发的Salus Pro测序仪获国家药监局（NMPA）三类医疗器械注册证，成为 国内首个基于可逆末端终止测序法实现全应用场景覆盖的国产设备，完美提供了因美纳被禁后国产测序 仪优选方案。公司坚持以"技术自主+产业闭环"为核心，已建成光学、流体、芯片、试剂等全链条研发 体系，打造全国产化测序+超分辨空间组学平台，累计授权专利超百项，产品覆盖科研、临床及农业领 域，致力于成为全球生命科学工具领军者。 投资界5月14日消息，近日，深圳赛陆医疗科技有限公司（以下简称：赛陆医疗）宣布完成A+轮融资。 本轮融资由医疗健康行业龙头企业复星医药领投，常州伟驰投资跟投，老股东深创投继续追加投资。本 轮资金将重点用于全国产测序平台的注册申报、产能扩建及全球化市场拓展，进一步巩固其在生命科学 工具领域的创新引领地位。 赛陆医疗创办于2020年，是国家高新技术企业和国家专精特新小巨人企业，专注于开发自主知识产权的 上游测序平台，并基于其上构建了全球领先的超分辨空间组学平台，实现基因组学和空间组学产品的自 主开发及科研临床端转化。公司突破了以往测序和组学产品在通量、成本、分辨率、自动化等方面的瓶 颈，取得国家 ...